LAUSANNE, Switzerland and NEWTOWN, Pennsylvania, February 26 /PRNewswire/ --
- Products and Pipeline to Enhance Galderma's Position in Dermatology
Galderma Pharma S.A., a global specialty pharmaceutical company focused on dermatology, and CollaGenex Pharmaceuticals, Inc. (Nasdaq: CGPI) today announced a definitive agreement pursuant to which Galderma's U.S. holding company, Galderma Laboratories, Inc., will acquire all of the outstanding shares of CollaGenex at a price of US$16.60 per share in cash, representing approximately US$420 million for the equity of CollaGenex. The transaction was unanimously approved by the boards of directors of Galderma and CollaGenex.